12:00 AM
 | 
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Viread tenofovir disoproxil fumarate regulatory update

FDA approved an sNDA from Gilead for once-daily 150, 200 and 250 mg oral tablets of Viread tenofovir disoproxil fumarate to treat HIV-1 infection in children ages 6-12 years. The nucleotide analog prodrug reverse transcriptase inhibitor is already available as a 300...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >